Skip to main content

Sterling enters second investment phase

1st December 2021

Submitted by:

Andrew Warmington

CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.

This will include a 4.5 m3 hydrogenator operating at up to 10 bar of pressure, and additional conical and filter dryers within the existing manufacturing plant. New kilo-scale and technology laboratories will be installed in the Material Science Centre, which was itself built in the previous phase of investment in 2020. These will be equipped to develop commercial-scale processes using biocatalysis and to enhance capabilities at the recently established flow chemistry centre of excellence.

“The next phase of our strategic plan is to increase and enhance our capacity to develop and scale up processes for commercial readiness, and is testament to the continued, strong interest that we are seeing in small molecule development,” said CEO Kevin Cook.

Separately, Sterling has announced an exclusive partnership with the University of Manchester’s Institute of Biotechnology (MIB), to provide chemical scale-up and process development expertise in the manufacture of molnupiravir, a new anti-viral drug for the treatment of COVID-19. With funding from the Bill and Melinda Gates Foundation, MIB developed a new route in which the use of a novel enzyme, cytidine aminotransferase, could reduce the manufacturing cost. The process has been transferred to Dudley to scale up to multi-kilos, using Sterling’s biocatalysis expertise.

Molnupiravir itself was originally developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme. On 4 November, the UK’s Medicines &Healthcare products Regulatory Agency (MHRA) approved it for the treatment of COVID-19. The parties envisage that the cheaper route could enable the drug to be made by generics companies and more widely used in poorer parts of the world.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington